Dasatinib induces severe hemorrhagic colitis in a patient with accelerated phase of chronic myelogenous leukemia

Korean J Intern Med. 2018 Mar;33(2):446-448. doi: 10.3904/kjim.2015.325. Epub 2016 Mar 10.

Authors

Eunjung Yim¹, Yeon-Geun Choi¹, Yoon-Jeong Nam¹, Jain Lee¹, Jeong-A Kim¹

Affiliation

¹ Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.

No abstract available

Keywords: Dasatinib; Hemorrhagic colitis; Leukemia, myelogenous, chronic, BCR-ABL positive.

Publication types

Case Reports

MeSH terms

Antineoplastic Agents* / adverse effects
Colitis* / chemically induced
Dasatinib* / adverse effects
Fusion Proteins, bcr-abl
Hemorrhage* / chemically induced
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
Male
Middle Aged
Protein Kinase Inhibitors
Thiazoles

Substances

Antineoplastic Agents
Protein Kinase Inhibitors
Thiazoles
Imatinib Mesylate
Fusion Proteins, bcr-abl
Dasatinib